Literature DB >> 24700365

Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma.

Taro Yamashita1, Azusa Kitao, Osamu Matsui, Takehiro Hayashi, Kouki Nio, Mitsumasa Kondo, Naoki Ohno, Tosiaki Miyati, Hikari Okada, Tatsuya Yamashita, Eishiro Mizukoshi, Masao Honda, Yasuni Nakanuma, Hiroyuki Takamura, Tetsuo Ohta, Yasunari Nakamoto, Masakazu Yamamoto, Tadatoshi Takayama, Shigeki Arii, XinWei Wang, Shuichi Kaneko.   

Abstract

UNLABELLED: The survival of patients with hepatocellular carcinoma (HCC) is often individually different even after surgery for early-stage tumors. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) has been introduced recently to evaluate hepatic lesions with regard to vascularity and the activity of the organic anion transporter OATP1B3. Here we report that Gd-EOB-DTPA-enhanced MRI (EOB-MRI) in combination with serum alpha-fetoprotein (AFP) status reflects the stem/maturational status of HCC with distinct biology and prognostic information. Gd-EOB-DTPA uptake in the hepatobiliary phase was observed in ∼15% of HCCs. This uptake correlated with low serum AFP levels, maintenance of hepatocyte function with the up-regulation of OATP1B3 and HNF4A expression, and good prognosis. By contrast, HCC showing reduced Gd-EOB-DTPA uptake with high serum AFP levels was associated with poor prognosis and the activation of the oncogene FOXM1. Knockdown of HNF4A in HCC cells showing Gd-EOB-DTPA uptake resulted in the increased expression of AFP and FOXM1 and the loss of OATP1B3 expression accompanied by morphological changes, enhanced tumorigenesis, and loss of Gd-EOB-DTPA uptake in vivo. HCC classification based on EOB-MRI and serum AFP levels predicted overall survival in a single-institution cohort (n=70), and its prognostic utility was validated independently in a multi-institution cohort of early-stage HCCs (n=109).
CONCLUSION: This noninvasive classification system is molecularly based on the stem/maturation status of HCCs and can be incorporated into current staging practices to improve management algorithms, especially in the early stage of disease.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24700365      PMCID: PMC4142120          DOI: 10.1002/hep.27093

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  37 in total

1.  A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells.

Authors:  Ju-Seog Lee; Jeonghoon Heo; Louis Libbrecht; In-Sun Chu; Pal Kaposi-Novak; Diego F Calvisi; Arsen Mikaelyan; Lewis R Roberts; Anthony J Demetris; Zongtang Sun; Frederik Nevens; Tania Roskams; Snorri S Thorgeirsson
Journal:  Nat Med       Date:  2006-03-12       Impact factor: 53.440

2.  The Forkhead Box m1b transcription factor is essential for hepatocyte DNA replication and mitosis during mouse liver regeneration.

Authors:  Xinhe Wang; Hiroaki Kiyokawa; Margaret B Dennewitz; Robert H Costa
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-13       Impact factor: 11.205

Review 3.  Prognostic prediction in patients with hepatocellular carcinoma.

Authors:  Margarita Sala; Alejandro Forner; Maria Varela; Jordi Bruix
Journal:  Semin Liver Dis       Date:  2005       Impact factor: 6.115

4.  A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.

Authors:  Josep M Llovet; Yingbei Chen; Elisa Wurmbach; Sasan Roayaie; M Isabel Fiel; Myron Schwartz; Swan N Thung; Gregory Khitrov; Weijia Zhang; Augusto Villanueva; Carlo Battiston; Vincenzo Mazzaferro; Jordi Bruix; Samuel Waxman; Scott L Friedman
Journal:  Gastroenterology       Date:  2006-09-19       Impact factor: 22.682

5.  Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor.

Authors:  Vladimir V Kalinichenko; Michael L Major; Xinhe Wang; Vladimir Petrovic; Joseph Kuechle; Helena M Yoder; Margaret B Dennewitz; Brian Shin; Abhishek Datta; Pradip Raychaudhuri; Robert H Costa
Journal:  Genes Dev       Date:  2004-04-01       Impact factor: 11.361

6.  Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor-4alpha gene.

Authors:  Chuan Yin; Yong Lin; Xin Zhang; Yue-Xiang Chen; Xin Zeng; Hai-Yan Yue; Jun-Liang Hou; Xing Deng; Jun-Ping Zhang; Ze-Guang Han; Wei-Fen Xie
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

7.  Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

Authors:  Yujin Hoshida; Augusto Villanueva; Masahiro Kobayashi; Judit Peix; Derek Y Chiang; Amy Camargo; Supriya Gupta; Jamie Moore; Matthew J Wrobel; Jim Lerner; Michael Reich; Jennifer A Chan; Jonathan N Glickman; Kenji Ikeda; Masaji Hashimoto; Goro Watanabe; Maria G Daidone; Sasan Roayaie; Myron Schwartz; Swan Thung; Helga B Salvesen; Stacey Gabriel; Vincenzo Mazzaferro; Jordi Bruix; Scott L Friedman; Hiromitsu Kumada; Josep M Llovet; Todd R Golub
Journal:  N Engl J Med       Date:  2008-10-15       Impact factor: 91.245

8.  EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma.

Authors:  Taro Yamashita; Marshonna Forgues; Wei Wang; Jin Woo Kim; Qinghai Ye; Huliang Jia; Anuradha Budhu; Krista A Zanetti; Yidong Chen; Lun-Xiu Qin; Zhao-You Tang; Xin Wei Wang
Journal:  Cancer Res       Date:  2008-03-01       Impact factor: 12.701

Review 9.  Cancer stem cells in the development of liver cancer.

Authors:  Taro Yamashita; Xin Wei Wang
Journal:  J Clin Invest       Date:  2013-05-01       Impact factor: 14.808

Review 10.  Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications.

Authors:  Peter Reimer; Günter Schneider; Wolfgang Schima
Journal:  Eur Radiol       Date:  2004-02-25       Impact factor: 5.315

View more
  46 in total

Review 1.  Trafficking and other regulatory mechanisms for organic anion transporting polypeptides and organic anion transporters that modulate cellular drug and xenobiotic influx and that are dysregulated in disease.

Authors:  Michael Murray; Fanfan Zhou
Journal:  Br J Pharmacol       Date:  2017-04-24       Impact factor: 8.739

Review 2.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

Review 3.  Functional imaging of hepatocellular carcinoma.

Authors:  Tim Ch Hoogenboom; Mark Thursz; Eric O Aboagye; Rohini Sharma
Journal:  Hepat Oncol       Date:  2016-03-29

Review 4.  Current status of imaging biomarkers predicting the biological nature of hepatocellular carcinoma.

Authors:  Norihide Yoneda; Osamu Matsui; Satoshi Kobayashi; Azusa Kitao; Kazuto Kozaka; Dai Inoue; Kotaro Yoshida; Tetsuya Minami; Wataru Koda; Toshifumi Gabata
Journal:  Jpn J Radiol       Date:  2019-02-02       Impact factor: 2.374

5.  Breakthrough Imaging in Hepatocellular Carcinoma.

Authors:  M Kudo
Journal:  Liver Cancer       Date:  2015-12-18       Impact factor: 11.740

6.  Beneficial Effect of Maintaining Hepatic Reserve during Chemotherapy on the Outcomes of Patients with Hepatocellular Carcinoma.

Authors:  Takeshi Terashima; Tatsuya Yamashita; Kuniaki Arai; Kazunori Kawaguchi; Kazuya Kitamura; Taro Yamashita; Yoshio Sakai; Eishiro Mizukoshi; Masao Honda; Shuichi Kaneko
Journal:  Liver Cancer       Date:  2017-05-17       Impact factor: 11.740

7.  Elevated expression of UHRF1 predicts unfavorable prognosis for patients with hepatocellular carcinoma.

Authors:  Dong Liang; Huanzhou Xue; Yang Yu; Feng Lv; Wei You; Bin Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

Review 8.  Clinico-Radio-Pathological and Molecular Features of Hepatocellular Carcinomas with Keratin 19 Expression.

Authors:  Hyungjin Rhee; Haeryoung Kim; Young Nyun Park
Journal:  Liver Cancer       Date:  2020-10-23       Impact factor: 11.740

9.  High expression of ubiquitin-conjugating enzyme E2A predicts poor prognosis in hepatocellular carcinoma.

Authors:  Jian-Dong Shen; Shou-Zhong Fu; Lin-Ling Ju; Yi-Fang Wang; Feng Dai; Zhao-Xiu Liu; Han-Zheng Ji; Jian-Guo Shao; Zhao-Lian Bian
Journal:  Oncol Lett       Date:  2018-03-07       Impact factor: 2.967

Review 10.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.